Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder

Inclusion Criteria: * The patient is judged to benefit from adjunctive treatment with brexpiprazole according to the clinical opinion of the investigator. * The patient had MDD at entry in lead-in brexpiprazole studies, NCT01838681 / 14570A or NCT01837797 / 14571A, diagnosed according to DSM-IV-TR™. * The patient agrees to protocol-defined use of effective contraception. Exclusion Criteria: * The patient has a disease or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study. * The patient has been diagnosed with a psychiatric disorder other than MDD during the lead-in studies NCT01838681 / 14570A or NCT01837797 / 14571A. * The patient, in the opinion of the investigator or according to C-SSRS, is at significant risk of suicide. * The patient has any relevant medical history or current presence of systemic disease. * The patient has, at the Baseline Visit an abnormal ECG that is, in the investigator's opinion, clinically significant. * The patient has a moderate or severe ongoing adverse event related to study medication from the lead-in studies considered of potential safety risk by the investigator. * The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason. Other inclusion and exclusion criteria may apply.